National Resilience

San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
mRNA Cell Therapy Lentiviral
9 confirmed programs · 8 sponsors · Last scored 2026-03-15
75.0
Signal Score
○ FDA Inspections ✓ Clinical Trials (9) ○ SEC Filings ✓ Press (3)

Quick Facts: National Resilience

Signal Score
75.0/100 (as of 2026-03-15)
Quality Compliance
100.0/100 — No FDA inspection records found for this manufacturer
Headquarters
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Modalities
mRNA, Cell Therapy, Lentiviral
Active CGT Programs
9 confirmed from ClinicalTrials.gov across 8 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance 100.0
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Source: FDA Data Dashboard
No FDA inspection records found for this manufacturer · Quality score requires FDA inspection data
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 60.0
9 active programs across 8 sponsors
Modalities: mRNA, Cell Therapy, Gene Therapy
3 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
9 active programs across 8 sponsors · Modalities: mRNA, Cell Therapy, Gene Therapy · 3 programs in advanced phases (Phase 2/3)
Programs 9
Sponsors8
ModalitiesmRNA, Cell Therapy, Lentiviral
9 active programs across 8 sponsors
Modalities: mRNA, Cell Therapy, Gene Therapy
3 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
Partnership Announcements (from press monitoring)
NCT07190755 Impact of Patient-Reported Outcomes for Symptom Monitoring in... NA Recruiting
NCT06364631 CARE1 Pragmatic Clinical Trial PHASE3 Recruiting
NCT06072612 Study of the Bria-IMT Regimen and CPI vs Physicians' Choice... PHASE3 Recruiting
NCT05835895 Safety and Pharmacodynamics of GNSC-001 Intra-articular... PHASE1 Active Not Recruiting
NCT05298293 Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma NA Not Yet Recruiting
NCT04023071 FT516 in Subjects With Advanced Hematologic Malignancies PHASE1 Terminated
NCT04093622 Long-term Follow-Up Study Following Treatment With Fate... NA Terminated
NCT00073463 Safety and Efficacy of Recombinant Adeno-Associated Virus... PHASE2/PHASE3 Terminated
NCT03601442 CTL019 Out of Specification MAP for ALL or DLBCL Patients NA Available
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 65.0
3 CGT manufacturing sites
Sites: Research Triangle Park, NC, Boston, MA, San Diego, CA
Source: SEC EDGAR, press monitoring, company profiles
3 CGT manufacturing sites
StatusAvailable
3 CGT manufacturing sites
Sites: Research Triangle Park, NC, Boston, MA, San Diego, CA
Recent Press3 articles
3 CGT manufacturing sites

Recent News 3 articles

partnership 2026-03-06
Taiwan unveils $755M multi-year drug supply resilience program - Fierce Pharma
Taiwan earmarks $755M for multi-year drug supply resilience program  Fierce Pharma
Source →
general 2026-03-04
Building stronger governance for Australia’s critical-minerals future - The Strategist | ASPI's analysis and commentary site
Building stronger governance for Australia’s critical-minerals future  The Strategist | ASPI's analysis and commentary site
Source →
general 2026-03-03
Make UK to call for new national resilience vision at manufacturing conference - PES Media
Make UK to call for new national resilience vision at manufacturing conference  PES Media
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
mRNA CDMOs → Cell Therapy CDMOs → Lentiviral CDMOs →